Amber L. Johns

34.7k total citations
28 papers, 1.0k citations indexed

About

Amber L. Johns is a scholar working on Oncology, Cancer Research and Surgery. According to data from OpenAlex, Amber L. Johns has authored 28 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 14 papers in Cancer Research and 5 papers in Surgery. Recurrent topics in Amber L. Johns's work include Pancreatic and Hepatic Oncology Research (19 papers), Cancer Genomics and Diagnostics (13 papers) and Neuroendocrine Tumor Research Advances (4 papers). Amber L. Johns is often cited by papers focused on Pancreatic and Hepatic Oncology Research (19 papers), Cancer Genomics and Diagnostics (13 papers) and Neuroendocrine Tumor Research Advances (4 papers). Amber L. Johns collaborates with scholars based in Australia, United Kingdom and United States. Amber L. Johns's co-authors include Andrew V. Biankin, Anthony J. Gill, David K. Chang, James G. Kench, Neil D. Merrett, Emily K. Colvin, Christopher J. Scarlett, Jaswinder S. Samra, Nam Q. Nguyen and Peter H. Cosman and has published in prestigious journals such as Journal of Clinical Oncology, Gastroenterology and PLoS ONE.

In The Last Decade

Amber L. Johns

28 papers receiving 983 citations

Peers

Countries citing papers authored by Amber L. Johns

Since Specialization

Citations

This map shows the geographic impact of Amber L. Johns's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amber L. Johns with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amber L. Johns more than expected).

Fields of papers citing papers by Amber L. Johns

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amber L. Johns. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amber L. Johns. The network helps show where Amber L. Johns may publish in the future.

Co-authorship network of co-authors of Amber L. Johns

This figure shows the co-authorship network connecting the top 25 collaborators of Amber L. Johns. A scholar is included among the top collaborators of Amber L. Johns based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amber L. Johns. Amber L. Johns is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	MA15.04 Timing of Pre-Biopsy COVID-mRNA Vaccination and PD-L1 Expression in Advanced Non-Small Cell Lung Cancer 2023 ·Journal of Thoracic Oncology ·Adam Grippin, Brian De, Katharina Fink, David A. Swanson, Charles Y.F. Young, Ellen T. Chang, Amber L. Johns, Edward Cha, (unknown), Stephanie O. Dudzinski, Jeff Lewis, (unknown), (unknown), J. Jack Lee, J. Zhang, (unknown), (unknown), John V. Heymach, Steven H. Lin	1
2	Accelerating cancer omics and precision oncology in health care and research: a Lancet Oncology Commission 2023 ·The Lancet Oncology ·Raffaella Casolino, Amber L. Johns, Mélanie Courtot, Rita T. Lawlor, Francesco De Lorenzo, Denis Horgan, Joaquı́n Mateo, Nicola Normanno, Mark A. Rubin, Lincoln Stein, Vivek Subbiah, (unknown), Mark Lawler, Keunchil Park, Sandra Pérdomo, Takayuki Yoshino, Jianmin Wu, Andrew V. Biankin	4
3	ICGC-ARGO precision medicine: an update on familial matters in pancreatic cancer 2022 ·The Lancet Oncology ·Michèle Milella, Rita T. Lawlor, Claudio Luchini, Amber L. Johns, Raffaella Casolino, Takayuki Yoshino, Andrew V. Biankin, Aldo Scarpa	3
4	Significant detection of new germline pathogenic variants in Australian Pancreatic Cancer Screening Program participants 2021 ·Hereditary Cancer in Clinical Practice ·Krithika Murali, Tanya Dwarte, Mehrdad Nikfarjam, Kathy Tucker, Rhys Vaughan, Marios Efthymiou, Allison Collins, Allan D. Spigelman, Lucinda Salmon, Amber L. Johns, David Williams, Martin B. Delatycki, Thomas John, Alina Stoita	5
5	Return of individual research results from genomic research: A systematic review of stakeholder perspectives 2021 ·PLoS ONE ·Danya F. Vears, Joel T. Minion, (unknown), James Cummings, Mavis Machirori, Mwenza Blell, Isabelle Budin‐Ljøsne, (unknown), Stephanie O. M. Dyke, Clara Gaff, Robert C. Green, Alison Hall, Amber L. Johns, Bartha Maria Knoppers, (unknown), Christine Patch, Eva C. Winkler, Madeleine J. Murtagh	34
6	The Impact of Molecular Subtyping on Pathological Staging of Pancreatic Cancer 2021 ·HPB ·Stephan B. Dreyer, S. Rae, Rosanna Upstill‐Goddard, Amber L. Johns, Antonio Pea, (unknown), Andrew V. Biankin, (unknown), Nigel B. Jamieson	1
7	MCL-1 antagonism enhances the anti-invasive effects of dasatinib in pancreatic adenocarcinoma 2019 ·Oncogene ·(unknown), Lesley Castillo, Adelaide I.J. Young, Amanda Mawson, (unknown), Angela Steinmann, (unknown), Ashleigh Parkin, Amber L. Johns, Angela Chou, Andrew M. K. Law, Morghan C. Lucas, Kendelle J. Murphy, Niantao Deng, David Gallego‐Ortega, Catherine E Caldon, Paul Timpson, Marina Pajic, Christopher J. Ormandy, Samantha R. Oakes	16
8	Genetic counselling and personalised risk assessment in the Australian pancreatic cancer screening program 2019 ·Hereditary Cancer in Clinical Practice ·Tanya Dwarte, Skye McKay, Amber L. Johns, Kathy Tucker, Allan D. Spigelman, David Williams, Alina Stoita	7
9	Provenance and risk in transfer of biological materials 2018 ·PLoS Biology ·Jane Nielsen, Tania Bubela, Drc Chalmers, Amber L. Johns, (unknown), Joanne Kamens, Charles Lawson, John Liddicoat, Rebekah McWhirter, (unknown), James Scheibner, Tess Whitton, Dianne Nicol	12
10	Delineating the Role of βIV-Tubulins in Pancreatic Cancer: βIVb-Tubulin Inhibition Sensitizes Pancreatic Cancer Cells to Vinca Alkaloids 2016 ·Neoplasia ·George Sharbeen, Joshua A. McCarroll, (unknown), Janet Youkhana, (unknown), Andrew V. Biankin, Amber L. Johns, Maria Kavallaris, David Goldstein, Phoebe A. Phillips	14
11	Abstract A02: Assessment of germline cancer predisposition genes in 392 unselected pancreatic cancer patients 2016 ·Cancer Research ·Skye McKay, Jeremy L. Humphris, Amber L. Johns, Mark Pinese, Ann‐Marie Patch, Kátia Nones, (unknown), Sean M. Grimmond, Andrew V. Biankin, Nicola Waddell	2
12	Abstract CT210: Precision medicine for advanced pancreas cancer: the individualized molecular pancreatic cancer therapy (IMPaCT) trial 2015 ·Cancer Research ·Lorraine A. Chantrill, Skye H. Simpson, Amber L. Johns, (unknown), Angela Chou, Clare Watson, Adnan Nagrial, Venessa Chin, Lucille Sebastian, Sonia Yip, John Simes, Nick Pavlakis, Peter Grimison, Ray Asghari, Sandra Harvey, Andrew V. Biankin	1
13	Returning individual research results for genome sequences of pancreatic cancer 2014 ·Genome Medicine ·Amber L. Johns, David K. Miller, Skye H. Simpson, Anthony J. Gill, Karin S. Kassahn, Jeremy L. Humphris, Jaswinder S. Samra, Katherine Tucker, Lesley Andrews, David K. Chang, Nicola Waddell, Marina Pajic, (unknown), John V. Pearson, Sean M. Grimmond, Andrew V. Biankin, Nikolajs Zeps	14
14	Adjuvant chemotherapy in elderly patients with pancreatic cancer 2013 ·British Journal of Cancer ·(unknown), Adnan Nagrial, David K. Chang, Nam Q. Nguyen, Amber L. Johns, Lorraine A. Chantrill, Jeremy L. Humphris, Venessa Chin, Jaswinder S. Samra, Anthony J. Gill, Marina Pajic, Mark Pinese, Emily K. Colvin, Christopher J. Scarlett, Angela Chou, James G. Kench, R. L. Sutherland, Lisa G. Horvath, Andrew V. Biankin	52
15	The prognostic and predictive value of serum CA19.9 in pancreatic cancer 2012 ·Annals of Oncology ·Jeremy L. Humphris, David K. Chang, Amber L. Johns, Christopher J. Scarlett, Marina Pajic, Marc D. Jones, Emily K. Colvin, Adnan Nagrial, Venessa Chin, Lorraine A. Chantrill, Jaswinder S. Samra, Anthony J. Gill, James G. Kench, Neil D. Merrett, Anibh M. Das, Elizabeth A. Musgrove, R. L. Sutherland, Andrew V. Biankin	221
16	The Wnt/β-catenin pathway drives increased cyclin D1 levels in lymph node metastasis in papillary thyroid cancer 2011 ·Human Pathology ·Jingdong Zhang, Anthony J. Gill, (unknown), (unknown), Amber L. Johns, Leigh Delbridge, Raymond Lai, Todd McMullen	59
17	Upregulation of the signal transducers and activators of transcription 3 (STAT3) pathway in lymphatic metastases of papillary thyroid cancer. 2011 ·PubMed ·Jingdong Zhang, Anthony J. Gill, (unknown), Amber L. Johns, Leigh Delbridge, Raymond Lai, Todd McMullen	28
18	Clinical and immunohistochemical features of 34 solid pseudopapillary tumors of the pancreas 2010 ·Journal of Gastroenterology and Hepatology ·Nam Q. Nguyen, Amber L. Johns, Anthony J. Gill, (unknown), David K. Chang, (unknown), Neil D. Merrett, James G. Kench, Emily K. Colvin, Christopher J. Scarlett, Andrew V. Biankin	49
19	Synoptic reporting improves histopathological assessment of pancreatic resection specimens 2008 ·Pathology ·Anthony J. Gill, Amber L. Johns, Robert P. Eckstein, Jaswinder S. Samra, (unknown), David K. Chang, Neil D. Merrett, Peter H. Cosman, Ross C. Smith, Andrew V. Biankin, James G. Kench	87
20	A double-blind placebo controlled trial to study the efficacy and safety of a low molecular weight heparin fragment (fragmin) in patients having major elective general surgery 1987 ·Thrombosis Research ·Paul Ockelford, Patrick Kesteven, (unknown), Nathan Brand, Amber L. Johns	9

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact